文献速递淋巴瘤

度伐利尤单抗(抗PD-L1)联合来那度胺治疗复发/难治性皮肤T细胞淋巴瘤的1期试验

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

这项1/2期临床试验评估度伐利尤单抗联合来那度胺治疗难治/晚期皮肤T细胞淋巴瘤的安全性和耐受性,确定来那度胺最大耐受剂量和推荐的2期剂量。13例可评估毒性,12例可评估剂量决策和疗效。第1至3周期未观察到严重不良事件或剂量限制性毒性,剂量水平3确定为推荐的2期剂量。最常见不良事件为肿瘤 flare、疲乏、中性粒细胞减少和白细胞减少。最佳总体缓解率和皮肤缓解率分别为58.3%(95%CI 27.7-84.8%)和75%(95%CI 42.8-94.5%),中位治疗周期11,中位缓解持续时间25.5个月。

要点

  • 第1至3周期未观察到严重不良事件或剂量限制性毒性,剂量水平3确定为推荐的2期剂量。
  • 最佳总体缓解率58.3%(95%CI 27.7-84.8%),皮肤缓解率75%(95%CI 42.8-94.5%)。
  • 中位治疗周期11,中位缓解持续时间25.5个月,7例部分缓解和4例疾病稳定。

核心结论

  • 度伐利尤单抗联合来那度胺在难治/晚期皮肤T细胞淋巴瘤中显示出临床活性,7例部分缓解和4例疾病稳定。

研究设计与样本

  • 1/2期临床试验,评估度伐利尤单抗联合来那度胺治疗难治/晚期皮肤T细胞淋巴瘤的安全性和耐受性,确定来那度胺最大耐受剂量和推荐的2期剂量。
  • 13例可评估毒性,12例可评估剂量决策和缓解。

主要发现

  • 第1至3周期(剂量限制性毒性评估期)未观察到严重不良事件或剂量限制性毒性,剂量水平3确定为推荐的2期剂量。
  • 最常见不良事件为肿瘤 flare、疲乏、中性粒细胞减少和白细胞减少。
  • 3例发生1级或2级自身免疫性甲状腺炎,经治疗缓解。
  • 最佳总体缓解率为58.3%(95%CI 27.7-84.8%),皮肤缓解率为75%(95%CI 42.8-94.5%)。
  • 中位治疗周期为11,中位缓解持续时间为25.5个月。

关键数值与推荐

  • 剂量水平3确定为推荐的2期剂量。
  • 最佳总体缓解率58.3%(95%CI 27.7-84.8%),皮肤缓解率75%(95%CI 42.8-94.5%)。
  • 缓解者中潜在预测性免疫特征为NF-κB介导的α信号、干扰素γ和磷脂酰肌醇3激酶-AKT-哺乳动物雷帕霉素靶蛋白信号通路下调。
  • 非缓解者中MYC靶点和促炎通路上调。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selective targeting of the functionally exhausted malignant T cells in cutaneous T-cell lymphoma (CTCL) and distinct cells within the tumor microenvironment (TME) via programmed cell death 1/programmed cell death ligand 1 blockade (durvalumab) may restore an antitumor immune response. The oral immunomodulator lenalidomide, which has activity in CTCL, may enhance durvalumab immune checkpoint blockade. Our phase 1/2 clinical trial of durvalumab and lenalidomide in patients with refractory/advanced CTCL sought to assess the safety and tolerability and to identify the maximum tolerated dose and recommended phase 2 dose (RP2D) of lenalidomide plus fixed-dose durvalumab. Secondary and tertiary objectives were to investigate the efficacy and effects on the TME. Thirteen patients were evaluable for toxicities and 12 for dose decisions and response. No serious adverse events (AEs) or dose-limiting toxicities (DLTs) were observed during cycles 1 to 3 (DLT evaluation period), and dose level 3 was identified as the RP2D. The most frequent AEs were tumor flare, fatigue, neutropenia, and leukopenia. Three patients developed grade 1 or 2 autoimmune thyroiditis that resolved with treatment. Best overall and skin response rates were 58.3% (95% confidence interval (95% CI), 27.7-84.8%) and 75% (95% CI: 42.8-94.5%), respectively. The median cycles of treatment were 11, and the median duration of response was 25.5 months. The combination showed clinical activity with 7 partial responses and 4 stable disease. Potentially predictive immune signatures were downregulation of -α signaling via NF-κB, interferon gamma, and phosphoinositide 3 kinase-AKT-mammalian target of rapamycin signaling pathways in responders and upregulation of MYC targets and proinflammatory pathways in nonresponders. Profiling of immune cell compositions revealed changes in individual immune cell clusters based on treatment response. This trial was registered at www.ClinicalTrials.gov as #NCT03011814.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Querfeld C, Palmer J, Han Z, et al. Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. Blood Adv. 2025. PMID: 39951620. doi:10.1182/bloodadvances.2024014655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。